Are Patients with Asthma and Chronic Obstructive Pulmonary Disease Preferred Targets of COVID-19?
Dihia Hadj-Said (Department of Biochemistry and Microbiology, Faculty of Biological and Agricultural Sciences, Mouloud Mammeri University, Tizi-Ouzou, Algeria)
Karen A. Pescatore (Department of Psychology, Rowan University, Glassboro, NJ, USA)
Rachid Chahed (Cabinet Médical Privé, Spécialité de Pneumologie, Tizi-Ouzou, Algeria)
- Downloaded
- Viewed
Abstract
The coronavirus pandemic, known as coronavirus disease 2019 (COVID-19), is an infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus first identified in patients from Wuhan, China. Since December 2019, SARS-CoV-2 has spread swiftly around the world, infected more than 25 million people, and caused more than 800,000 deaths in 188 countries. Chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) appear to be risk factors for COVID-19, however, their prevalence remains controversial. In fact, studies in China reported lower rates of chronic respiratory conditions in patients with COVID-19 than in the general population, while the trend is reversed in the United States and Europe. Although the underlying molecular mechanisms of a possible interaction between COVID-19 and chronic respiratory diseases remain unknown, some observations can help to elucidate them. Indeed, physiological changes, immune response, or medications used against SARS-CoV-2 may have a greater impact on patients with chronic respiratory conditions already debilitated by chronic inflammation, dyspnea, and the use of immunosuppressant drugs like corticosteroids. In this review, we discuss importance and the impact of COVID-19 on asthma and COPD patients, the possible available treatments, and patient management during the pandemic.
- keywords
- COVID-19, SARS-CoV-2, Chronic Respiratory Diseases, Asthma, Chronic Obstructive Pulmonary Disease
Reference
1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-33.
2. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020;55:105924.
3. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5:536-44.
4. Conti P, Gallenga CE, Tete G, Caraffa A, Ronconi G, Younes A, et al. How to reduce the likelihood of coronavirus-19 (CoV19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1. J Biol Regul Homeost Agents 2020;34:333-8.
5. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet]. Geneva:World Health Organization; 2020 [cited 2020 Apr 22]. Available from: https://www.who.int/fr/dg/speeches/detail/whodirector-general-s-opening-remarks-at-the-media-briefingon-covid-19---11-march-2020.
6. Beckham JD, Cadena A, Lin J, Piedra PA, Glezen WP, Greenberg SB, et al. Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect 2005;50:322-30.
7. Papadopoulos NG, Christodoulou I, Rohde G, Agache I, Almqvist C, Bruno A, et al. Viruses and bacteria in acute asthma exacerbations: a GA(2) LEN-DARE systematic review. Allergy 2011;66:458-68.
8. Silva RC, Couceiro JN, Camara FP, Valle S, Santos N. Asthma exacerbation and viral infection in adult patients, Brazil. Braz J Infect Dis 2015;19:446-8.
9. Kherad O, Bridevaux PO, Kaiser L, Janssens JP, Rutschmann O. Viral infection in acute exacerbation of COPD. Rev Med Suisse 2011;7:2222-6.
10. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China. Allergy 2020;75:1730-41.
11. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 2020;71:769-77.
12. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 2020;92:797-806.
13. Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D. Early clinical and CT manifestations of coronavirus disease 2019(COVID-19) pneumonia. AJR Am J Roentgenol 2020;215:338-43.
14. Qian GQ, Yang NB, Ding F, Ma AHY, Wang ZY, Shen YF, et al. Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series. QJM 2020;113:474-81.
15. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020;323:1488-94.
16. Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging 2020;47:1275-80.
17. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020;77:683-90.
18. He F, Deng Y, Li W. Coronavirus disease 2019: What we know? J Med Virol 2020;92:719-25.
19. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9.
20. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
21. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 2020;323:2052-9.
22. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547.
23. Gold JA, Wong KK, Szablewski CM, Patel PR, Rossow J, da Silva J, et al. Characteristics and clinical outcomes of adult patients hospitalized with COVID-19 — Georgia, March 2020. MMWR Morb Mortal Wkly Rep 2020;69:545-50.
24. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:458-64.
25. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.
26. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020;323:1574-81.
27. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020;133:1025-31.
28. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020;94:91-5.
29. CDC COVID-19 Response Team. Coronavirus disease 2019in children — United States, February 12–April 2, 2020. MMWR Morb Mortal Wkly Rep 2020;69:422-6.
30. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-66.
31. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus [Internet]. Treasure Island: StatPearls Publishing; 2020 [cited 2020 Mar 25]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK554776/.
32. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci U S A 2004;101:4240-5.
33. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al. COVID-19-related genes in sputum cells in asthma: relationship to demographic features and corticosteroids. Am J Respir Crit Care Med 2020;202:83-90.
34. Izaguirre G. The proteolytic regulation of virus cell entry by furin and other proprotein convertases. Viruses 2019;11:837.
35. Perrier A, Bonnin A, Desmarets L, Danneels A, Goffard A, Rouille Y, et al. The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal. J Biol Chem 2019;294:14406-21.
36. Rokni M, Ghasemi V, Tavakoli Z. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran:comparison with SARS and MERS. Rev Med Virol 2020;30:e2107.
37. Deng X, van Geelen A, Buckley AC, O’Brien A, Pillatzki A, Lager KM, et al. Coronavirus endoribonuclease activity in porcine epidemic diarrhea virus suppresses type I and type III interferon responses. J Virol 2019;93:e02000-18.
38. Yang CH, Li K, Pfeffer SR, Pfeffer LM. The Type I IFN-Induced miRNA, miR-21. Pharmaceuticals (Basel) 2015;8:836-47.
39. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-2.
40. Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 2020;92:1518-24.
41. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020;20:425-34.
42. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol 2020;11:827.
43. South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol 2020;318:H1084-90.
44. Hewitt R, Farne H, Ritchie A, Luke E, Johnston SL, Mallia P. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis 2016;10:158-74.
45. Liao H, Yang Z, Yang C, Tang Y, Liu S, Guan W, et al. Impact of viral infection on acute exacerbation of asthma in outpatient clinics: a prospective study. J Thorac Dis 2016;8:505-12.
46. Top 10 causes of death [Internet]. Geneva: World Health Organization; 2018 [cited 2019 Nov 27]. Available from: http://www.who.int/gho/mortality_burden_disease/causes_death/top_10/en/.
47. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med 2020;8:e35.
48. Halpin DM, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med 2020;8:436-8.
49. Most recent national asthma data [Internet]. Atlanta: Centers for Disease Control and Prevention; 2020 [cited 2020May 8]. Available from: https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm.
50. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020;369:m1985.
51. Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020;63:1500-15.
52. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146:110-8.
53. Li YK, Peng S, Li LQ, Wang Q, Ping W, Zhang N, et al. Clinical and transmission characteristics of COVID-19: a retrospective study of 25 cases from a single thoracic surgery department. Curr Med Sci 2020;40:295-300.
54. Lian J, Jin X, Hao S, Cai H, Zhang S, Zheng L, et al. Analysis of epidemiological and clinical features in older patients with coronavirus disease 2019 (COVID-19) outside Wuhan. Clin Infect Dis 2020;71:740-7.
55. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect 2020;80:639-45.
56. Zhang JJ, Cao YY, Dong X, Wang BC, Liao MY, Lin J, et al. Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARSCoV-2. Allergy 2020;75:1809-12.
57. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study. Am J Respir Crit Care Med 2020;201:1372-9.
58. CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep 2020;69:382-6.
59. Dreher M, Kersten A, Bickenbach J, Balfanz P, Hartmann B, Cornelissen C, et al. The characteristics of 50 hospitalized COVID-19 patients with and without ARDS. Dtsch Arztebl Int 2020;117:271-8.
60. Huang K, Yang T, Xu J, Yang L, Zhao J, Zhang X, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet 2019;394:407-18.
61. Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet 2018;391:1706-17.
62. Croft JB, Wheaton AG, Liu Y, Xu F, Lu H, Matthews KA, et al. Urban-rural county and state differences in chronic obstructive pulmonary disease - United States, 2015. MMWR Morb Mortal Wkly Rep 2018;67:205-11.
63. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from metaanalysis. Aging (Albany NY) 2020;12:6049-57.
64. Xu G, Yang Y, Du Y, Peng F, Hu P, Wang R, et al. Clinical pathway for early diagnosis of COVID-19: updates from experience to evidence-based practice. Clin Rev Allergy Immunol 2020;59:89-100.
65. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002;532:107-10.
66. Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J 2020;55:2000688.
67. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol 2020;146:203-6.
68. Li G, He X, Zhang L, Ran Q, Wang J, Xiong A, et al. Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. J Autoimmun 2020;112:102463.
69. Dhawale VS, Amara VR, Karpe PA, Malek V, Patel D, Tikoo K. Activation of angiotensin-converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model. Toxicol Appl Pharmacol 2016;306:17-26.
70. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005;436:112-6.
71. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005;11:875-9.
72. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 2002;(82):S12-22.
73. Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19: a systematic review. Life Sci 2020;254:117788.
74. Manthei DM, Schwantes EA, Mathur SK, Guadarrama AG, Kelly EA, Gern JE, et al. Nasal lavage VEGF and TNF-alpha levels during a natural cold predict asthma exacerbations. Clin Exp Allergy 2014;44:1484-93.
75. Ying S, Robinson DS, Varney V, Meng Q, Tsicopoulos A, Moqbel R, et al. TNF alpha mRNA expression in allergic inflammation. Clin Exp Allergy 1991;21:745-50.
76. Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factoralpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 1995;152:76-80.
77. Huang AX, Lu LW, Liu WJ, Huang M. Plasma inflammatory cytokine IL-4, IL-8, IL-10, and TNF-alpha levels correlate with pulmonary function in patients with asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome. Med Sci Monit 2016;22:2800-8.
78. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8.
79. Garth J, Barnes JW, Krick S. Targeting cytokines as evolving treatment strategies in chronic inflammatory airway diseases. Int J Mol Sci 2018;19:3402.
80. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:1065-72.
81. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res 2016;118:145-56.
82. Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005;128:1995-2004.
83. Kasayama S, Tanemura M, Koga M, Fujita K, Yamamoto H, Miyatake A. Asthma is an independent risk for elevation of plasma C-reactive protein levels. Clin Chim Acta 2009;399:79-82.
84. Kilic H, Karalezli A, Hasanoglu HC, Erel O, Ates C. The relationship between hs-CRP and asthma control test in asthmatic patients. Allergol Immunopathol (Madr) 2012;40:362-7.
85. Fermont JM, Masconi KL, Jensen MT, Ferrari R, Di Lorenzo VAP, Marott JM, et al. Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis. Thorax 2019;74:439-46.
86. Manuyakorn W, Mairiang D, Sirachainan N, Kadegasem P, Kamchaisatian W, Benjaponpitak S, et al. Blood coagulation and asthma exacerbation in children. Int Arch Allergy Immunol 2016;170:75-83.
87. Zheng XY, Xu YJ, Guan WJ, Lin LF. Regional, age and respiratory-secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review. Arch Virol 2018;163:845-53.
88. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study. AJR Am J Roentgenol 2020;214:1072-7.
89. Kanne JP, Little BP, Chung JH, Elicker BM, Ketai LH. Essentials for radiologists on COVID-19: an update-Radiology Scientific Expert Panel. Radiology 2020;296:E113-4.
90. Andreassen SL, Liaaen ED, Stenfors N, Henriksen AH. Impact of pneumonia on hospitalizations due to acute exacerbations of COPD. Clin Respir J 2014;8:93-9.
91. Pelton SI, Shea KM, Bornheimer R, Sato R, Weycker D. Pneumonia in young adults with asthma: impact on subsequent asthma exacerbations. J Asthma Allergy 2019;12:95-9.
92. Rueter K, Bizzintino J, Martin AC, Zhang G, Hayden CM, Geelhoed GC, et al. Symptomatic viral infection is associated with impaired response to treatment in children with acute asthma. J Pediatr 2012;160:82-7.
93. Coronavirus disease (COVID-19) advice for public [Internet]. Geneva: World Health Organization; 2020 [cited 2020Apr 21]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public.
94. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020;14:58-60.
95. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of Lopinavir/Ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 2020;35:e79.
96. Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against corona virus sisease 2019: a retrospective cohort study. J Infect 2020;81:e1-e5.
97. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 2020;14:64-8.
98. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020;382:1787-99.
99. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of Remdesivir for patients with severe COVID-19. N Engl J Med 2020;382:2327-36.
100. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, doubleblind, placebo-controlled, multicentre trial. Lancet 2020;395:1569-78.
101. Beigel JH, Tomashek KM, Dodd LE. Remdesivir for the treatment of Covid-19: preliminary report. Reply. N Engl J Med 2020;383:994.
102. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.
103. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020;57:279-83.
104. Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 2007;30:297-308.
105. Borges MC, Castro LA, Fonseca BA. Chloroquine use improves dengue-related symptoms. Mem Inst Oswaldo Cruz 2013;108:596-9.
106. Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, Wills B, et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 2010;4:e785.
107. Algerian Ministry of Health. Coronavirus infection threat preparedness and response plan [Internet]. Algiers: Algerian Ministry of Health [cited 2020 Mar 31]. Available from:http://www.sante.gov.dz/prevention/.
108. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72-3.
109. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56:105949.
110. Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, et al. Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 2020;35:101738.
111. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19 — RECOVERY Trial [Internet]. Oxford: Nuffield Department of Population Health; 2020[cited 2020 Jun 7]. Available from: https://www.recoverytrial. net/news/statement-from-the-chief-investigators-of-therandomised-evaluation-of-covid-19-therapy-recovery-trialon-hydroxychloroquine-5-june-2020-no-clinical-benefitfrom-use-of-hydroxychloroquine-in-hospitalised-patientswith-covid-19.
112. AminJafari A, Ghasemi S. The possible of immunotherapy for COVID-19: A systematic review. Int Immunopharmacol 2020;83:106455.
113. Elbeddini A, Yeats A. Amid COVID-19 drug shortages:proposed plan for reprocessing and reusing salbutamol pressurized metered dose inhalers (pMDIs) for shared use. Drugs Ther Perspect 2020:1-3.
114. Zubillaga I, Frances C, Nicolau J, Homar F, Masmiquel L. Adrenal insufficiency and exogenous Cushing’s syndrome in a patient receiving inhaled fluticasone and ritonavir. Endocrinol Diabetes Nutr 2017;64:338-9.
115. Blondin MC, Beauregard H, Serri O. Iatrogenic Cushing syndrome in patients receiving inhaled budesonide and itraconazole or ritonavir: two cases and literature review. Endocr Pract 2013;19:e138-41.
116. Coronavirus disease 2019 (COVID-19) [Internet]. Atlanta: Centers for Disease Control and Prevention; 2020[cited 2020 Jun 3]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/asthma. html.
117. Nasim S, Kumar S, Azim D, Ashraf Z, Azeem Q. Corticosteroid use for 2019-nCoV infection: a double-edged sword. Infect Control Hosp Epidemiol 2020;41:1244-5.
118. Fang X, Mei Q, Yang T, Li L, Wang Y, Tong F, et al. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. J Infect 2020;81:147-78.
119. Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. Preprint at http://biorxiv.org/lookup/doi/10.1101/2020.03.11.987016(2020).
120. Iwabuchi K, Yoshie K, Kurakami Y, Takahashi K, Kato Y, Morishima T. Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: report of three cases. J Infect Chemother 2020;26:625-32.
121. Rothuizen LE, Livio F, Buclin T. Drugs that aggravate the course of COVID-19: really ?. Rev Med Suisse 2020;16:852-4.
122. Casale TB, Dykewicz MS. Clinical implications of the allergic rhinitis-asthma link. Am J Med Sci 2004;327:127-38.
123. ARIA [Internet]. Woluwe-Saint-Lambert: EUFOREA; 2020[cited 2020 Jun 3]. Available from: https://www.euforea.eu/aria.
124. Bousquet J, Akdis C, Jutel M, Bachert C, Klimek L, Agache I, et al. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: an ARIA-EAACI statement. Allergy 2020;75:2440-4.
125. Scadding GK, Hellings PW, Bachert C, Bjermer L, Diamant Z, Gevaert P, et al. Allergic respiratory disease care in the COVID-19 era: a EUFOREA statement. World Allergy Organ J 2020;13:100124.
126. Ding B, Kallenbach L, Slipski L, Wilk A, O’Brien D, Guranlioglu D. Patient characteristics and healthcare resource utilization among patients with COPD new to LAMA/LABA fixed-dose combination greatment in US-based real-world practice. Int J Chron Obstruct Pulmon Dis 2020;15:775-86.
127. Recio Iglesias J, Diez-Manglano J, Lopez Garcia F, Diaz Peromingo JA, Almagro P, Varela Aguilar JM. Management of the COPD patient with comorbidities: an experts recommendation document. Int J Chron Obstruct Pulmon Dis 2020;15:1015-37.
128. Ssieh RM. European Hypertension Society (ESH) statement on hypertension, regarding renin angiotensin system blockers and COVID-19 disease caused by the SARS-CoV-2 coronavirus [Internet]. Paris: French Society of Hypertension;2020 [cited 2020 May 29]. Available from: http://www.sfhta. eu/?p=6670.
129. Abrams EM, t Jong GW, Yang CL. Asthma and COVID-19. CMAJ 2020;192:E551.
- Downloaded
- Viewed
- 0KCI Citations
- 0WOS Citations